Breaking Down Hefei Meyer Optoelectronic Technology Inc. Financial Health: Key Insights for Investors

Hefei Meyer Optoelectronic's recent results pack contrasts that every investor should unpack: Q3 2025 revenue rose to 671 million yuan (+3.67% YoY) with TTM revenue of 2.43 billion yuan (+3.44% YoY) despite a 2024 annual revenue decline to 2.31 billion yuan (-4.73%); profitability remains notable with net income of 649 million yuan and a net margin of 28.1% in 2024 while gross margin eased to 50.4% (from 51.5%), ROE stood at 27.14% and EPS fell to 0.74 yuan from 0.85; balance-sheet strength is visible in cash and equivalents of 1.623 billion yuan versus only 55 million yuan of debt, supporting liquidity ratios (current ratio 4.14, quick ratio 3.57) and robust operating cash flow (880 million yuan in 2024, net operating cash inflow 393 million yuan, +125.28% YoY); market pricing implies a premium with a trailing P/E of 25.32, forward P/E 22.70, P/S 7.49 and an enterprise value/EBITDA of 20.89 as market cap climbed to 18.17 billion yuan (+35.74% YoY), while concentration risks (color sorting >70% of revenue, though that segment grew 9.9% in 2024) and a 33.4% YoY drop in CBCT medical-device sales underline why product launches like the AI+ Meiya Master 4.0 and the 10,000-user Meiya Meiya oral-health platform could be pivotal for the stock-read on for the full breakdown of metrics, valuation, risks and catalysts investors need to weigh

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Revenue Analysis

Key topline trends and segment breakdowns for Hefei Meyer Optoelectronic Technology Inc. (002690.SZ), focusing on recent quarterly, trailing twelve months (TTM) and annual figures, plus segment performance and productivity metrics.

• Q3 2025 revenue: 671 million yuan - +3.67% YoY versus Q3 2024.
• TTM revenue (as of 2025-09-30): 2.43 billion yuan - +3.44% YoY.
• Full-year 2024 revenue: 2.31 billion yuan - down 4.73% YoY from 2023.
• Revenue per employee: ~1.72 million yuan, indicating relatively high workforce productivity.

Segment performance (2024 year-over-year):

• Color sorting machines: +9.9% YoY contribution growth, a major positive driver within product mix.
• Medical equipment (CBCT devices): -33.4% YoY, materially negative impact on medical segment revenues.

Implications for revenue composition and investor attention:

• Growth is concentrated in industrial/products side (color sorting); medical device weakness is a notable drag.
• Stability indicated by modest YoY gains in TTM and Q3 2025, but full-year 2024 decline suggests some cyclicality or one-off headwinds.
• High revenue per employee (~1.72M yuan) suggests operational leverage-monitor margins and staffing trends to see if productivity sustains revenue growth.

Further company context and investor positioning: Exploring Hefei Meyer Optoelectronic Technology Inc. Investor Profile: Who's Buying and Why?

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Profitability Metrics

• Net income (2024): 649 million yuan, delivering a net profit margin of 28.1% (implying 2024 revenue ≈ 2,310.7 million yuan).
• Gross margin (2024): 50.4%, down from 51.5% in 2023.
• Operating margin (2024): 38.47%, indicating strong operational efficiency.
• Return on equity (ROE, 2024): 27.14%.
• Return on assets (ROA, 2024): 14.24%.
• Earnings per share (EPS): 0.74 yuan in 2024 vs. 0.85 yuan in 2023.

• High gross and operating margins signal pricing power and controlled operating costs despite a slight gross-margin compression year-over-year.
• ROE of 27.14% and ROA of 14.24% point to efficient capital and asset use relative to peers in optoelectronics.
• EPS decline (0.85 → 0.74) warrants investigation into share count changes, non-recurring items, or tax/finance costs affecting per-share earnings.

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Debt vs. Equity Structure

• Cash reserve dominance: cash of 1.623 billion yuan provides strong funding flexibility and liquidity coverage versus the 55 million yuan of debt.
• Minimal leverage: total debt represents a tiny fraction of cash holdings, signaling low reliance on external borrowing.
• Conservative capital mix: absence of short-term investments and low liabilities (per available data) point to a risk-averse treasury posture.

• Credit risk: low, given the combination of high cash and minimal debt outstanding.
• Refinancing risk: limited near-term pressure due to negligible debt load.
• Shareholder equity support: a strong cash base suggests equity capital is well-backed even if precise equity figures are not disclosed.

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Liquidity and Solvency

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) demonstrates a robust liquidity profile and healthy solvency metrics supported by strong cash generation and low leverage.

• Current ratio: 4.14 - indicates ample short-term assets relative to short-term liabilities.
• Quick ratio: 3.57 - shows immediate liquid assets comfortably cover near-term obligations.
• Net cash flow from operating activities (2024): ¥393 million - up 125.28% YoY, reflecting markedly improved cash conversion.
• Operating cash flow (2024): ¥880 million - a 30% increase vs. prior year, signaling stronger core cash generation.
• Substantial cash reserves combined with low debt levels enhance overall solvency and reduce refinancing risk.

Key implications for investors:

• The combination of a 4.14 current ratio and 3.57 quick ratio signals strong short-term resilience against liquidity shocks.
• Rapidly improving operating cash flows (¥880M, +30%) and a 125.28% jump in net operating cash inflows (¥393M) reduce dependence on external financing.
• Low debt levels and sizable cash reserves improve the company's ability to fund growth, weather downturns, and pursue strategic investments with limited refinancing risk.

Further context on corporate direction and values can be found here: Mission Statement, Vision, & Core Values (2026) of Hefei Meyer Optoelectronic Technology Inc.

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Valuation Analysis

Key valuation metrics for Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) indicate a premium market positioning relative to peers and reflect recent investor enthusiasm.

• Trailing P/E: 25.32 - moderate earnings multiple that prices current profitability.
• Forward P/E: 22.70 - market expects earnings growth or improving margins.
• Price-to-Sales (P/S): 7.49 - equity valued at a high multiple of revenue, signaling growth expectations or strong margin profile.
• EV/EBITDA: 20.89 - enterprise-level valuation suggesting limited near-term value leverage versus cash-flow generation.
• Market capitalization (12-Dec-2025): ¥18.17 billion - up 35.74% year-over-year, indicating positive investor sentiment.
• Overall: metrics imply a premium valuation relative to industry averages, requiring stronger growth or margin delivery to justify multiples.

• Implications for investors:
  • Premium multiples demand sustained revenue growth, margin expansion, or both.
  • Downside risk if growth misses expectations given elevated EV/EBITDA and P/S.
  • Positive sentiment evidenced by market-cap increase - monitor news flow and quarterly results for confirmation.

For broader context on shareholder composition and investor drivers, see: Exploring Hefei Meyer Optoelectronic Technology Inc. Investor Profile: Who's Buying and Why?

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Risk Factors

• Significant segmental weakness: The medical equipment segment (CBCT devices) recorded a 33.4% year‑over‑year revenue decline in 2024, materially weakening a previously growing business line.
• Slowing top‑line growth: Revenue growth has decelerated - average growth of 3.60% per year over the past 12 months versus 8.30% average annual growth over the past 3 years.
• Modest recent revenue expansion: Trailing twelve months (TTM) revenue as of 2025‑09‑30 was ¥2.43 billion, up 3.44% YoY, signalling slowed momentum.
• Profitability pressure: Key profitability metrics (net profit margin and EPS) have trended downward, which can erode investor confidence and valuation multiples.
• Concentration risk: Heavy reliance on the color sorting machine segment exposes the company to cyclical or demand shocks specific to that industry.
• Cross‑segment impact: Continued weakness in medical equipment (CBCT) could hamper overall corporate growth and cash‑flow generation going forward.

• Operational and financial risks to monitor:
  • Recovery trajectory for CBCT sales and timing of any rebound.
  • Margins and EPS trend reversals - watch quarterly net profit margin and diluted EPS figures.
  • Sustainability of revenue diversification away from color sorting machines.
  • Cash flow and balance sheet resilience if segment declines persist.

Hefei Meyer Optoelectronic Technology Inc. (002690.SZ) - Growth Opportunities

• Product roadmap: Meiya Master 4.0 (AI+ intelligent color sorting machine) is slated for commercial launch, expected to raise unit ASPs and automation value-add.
• Medical tailwinds: Economic recovery and increased elective dental procedures (implants, orthodontics) should lift demand for the company's oral-health digital and device offerings.
• Revenue concentration and margin expansion: Color sorting machines remain the core cash engine - contributing >70% of revenue while recording a material improvement in gross margin, indicating scalable unit economics.
• Digital platform traction: The Meiya Meiya cloud platform for oral health has exceeded 10,000 end users, creating recurring‑revenue and cross‑sell opportunities into devices and consumables.
• Balance sheet strength: Strong operating cash flow and low net debt provide flexibility to fund R&D, channel expansion and selective M&A to accelerate medical business penetration.

• Meiya Master 4.0 adoption curve - unit shipments, ASPs, and realized margin lift versus legacy models.
• Cross-sell conversion rates from Meiya Meiya users to paid services, consumables and medical devices.
• Recovery trajectory in dental implant and orthodontic procedures and resulting order book for medical-related hardware.
• R&D and capex allocation - continued investment into AI, edge vision and cloud integration versus return on invested capital.
• Balance-sheet deployment - use of net cash for organic scaling, channel expansion or tuck‑in acquisitions.